Many people who are confronted with the diagnosis of cancer place their hope in progress in medicine. Such progress to improve existing therapies or develop new cures is achieved primarily through clinical trials. Before a new drug is approved for the treatment of a disease, extensive and careful controls take place. Strict laws and a defined approval procedure apply in Germany. In a clinical trial, the new therapeutic procedure is tested on a selected group of people with regard to efficacy, safety and tolerability.
NCT/UCC-Early Clinical Trial Unit (ECTU)
The National Center for Tumor Diseases Dresden (NCT/UCC) has specialized in conducting early clinical trials with a specially established unit, the Early Clinical Trial Unit (ECTU). Through the ECTU, we now also want to provide patients with access to phase I studies in order to enable timely participation in medical progress. We are particularly interested in acquiring studies for patients with advanced diseases for which no standard therapy is available.
Our ECTU is located in the newly constructed Diagnostic Internal Medicine-Neurology Center, providing the highest level of safety and comfort for patients receiving treatment.
For consideration of possible study inclusion or if you have any questions, please feel free to contact us.
Senior physician PD Dr. med. habil. Martin Wermke
Specialist for internal medicine
Specialist in internal medicine and hematology and oncology
- Hematology and oncology
- National Center for Tumor Diseases Dresden (NCT/UCC)
- Director Trial Management / Early Clinical Trial Unit
Phone: +49 (0)351 458 7566
Fax: +49 (0)351 458 7261